Based on the findings that different TP53 mutation types can confer differential tumor biology on cancers [24], I propose that the lumping together of all the TP53 mutations as one subset in this study may have precluded a determination of the accurate extent of the relationship between PARPi response and TP53 mutation status. This evidence concerns the gene TP53 and cancer.